| scholarly article | Q13442814 |
| P50 | author | Philippe Beuzeboc | Q115467721 |
| Gemma Kenter | Q37828878 | ||
| P2093 | author name string | Christian Kurzeder | |
| Susy M E Scholl | |||
| P2860 | cites work | Total laparoscopic radical hysterectomy for locally advanced cervical carcinoma (stages IIB, IIA and bulky stages IB) after concurrent chemoradiation therapy: surgical morbidity and oncological results | Q84127898 |
| PTEN regulates angiogenesis and VEGF expression through phosphatase-dependent and -independent mechanisms in HepG2 cells | Q84133668 | ||
| BATTLE to personalize lung cancer treatment. Novel clinical trial design and tissue gathering procedures drive biomarker discovery | Q84524198 | ||
| EGFR inhibition as a therapy for head and neck squamous cell carcinoma | Q94706770 | ||
| Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation | Q21195230 | ||
| Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab | Q24313194 | ||
| Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 | Q27860674 | ||
| Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines | Q28166679 | ||
| Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer | Q28271324 | ||
| Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer | Q28308193 | ||
| PI3K/PTEN signaling in angiogenesis and tumorigenesis | Q28383083 | ||
| Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world | Q29614969 | ||
| The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis | Q29616121 | ||
| Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck | Q29619277 | ||
| Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex | Q31038919 | ||
| Identification of a specific inhibitor of the dishevelled PDZ domain | Q33227576 | ||
| Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors | Q33263277 | ||
| Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer | Q33360410 | ||
| Platinum-based chemotherapy plus cetuximab in head and neck cancer | Q33381094 | ||
| Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study | Q33406802 | ||
| Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2. | Q33468432 | ||
| Elevated levels of the polo kinase Cdc5 override the Mec1/ATR checkpoint in budding yeast by acting at different steps of the signaling pathway | Q33526233 | ||
| Homozygous deletion of the STK11/LKB1 locus and the generation of novel fusion transcripts in cervical cancer cells | Q33721668 | ||
| Convergence between Wnt-β-catenin and EGFR signaling in cancer | Q34149071 | ||
| Frequent deregulations in the hedgehog signaling network and cross-talks with the epidermal growth factor receptor pathway involved in cancer progression and targeted therapies | Q34244929 | ||
| Human papillomavirus can escape immune recognition through Langerhans cell phosphoinositide 3-kinase activation | Q34420097 | ||
| A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis | Q34637596 | ||
| A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells | Q34787867 | ||
| Mechanisms of human papillomavirus-induced oncogenesis. | Q35915935 | ||
| Inactivation of PTEN is associated with increased angiogenesis and VEGF overexpression in gastric cancer | Q36178164 | ||
| Expression of Ku70 correlates with survival in carcinoma of the cervix. | Q36621605 | ||
| CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection | Q36637922 | ||
| Nuclear epidermal growth factor receptor (EGFR) interacts with signal transducer and activator of transcription 5 (STAT5) in activating Aurora-A gene expression | Q36798731 | ||
| Nuclear mode of the EGFR signaling network: biology, prognostic value, and therapeutic implications | Q36798851 | ||
| Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer | Q36948707 | ||
| Mechanisms of disease: the PI3K-Akt-PTEN signaling node--an intercept point for the control of angiogenesis in brain tumors | Q37018652 | ||
| Optimizing Dvl PDZ domain inhibitor by exploring chemical space. | Q37111553 | ||
| EGFR-targeted therapies in lung cancer: predictors of response and toxicity | Q37160173 | ||
| Targeting metastatic colorectal cancer in 2008: a long way from 5-FU. | Q37160249 | ||
| Tumor-specific regulatory T cells in cancer patients | Q37166643 | ||
| Molecular Signature of HPV-Induced Carcinogenesis: pRb, p53 and Gene Expression Profiling | Q37236208 | ||
| KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. | Q37273361 | ||
| Papillomaviruses in the causation of human cancers - a brief historical account | Q37365856 | ||
| Combined chemotherapy and radiation therapy for cervical cancer. | Q37603271 | ||
| Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer | Q37634598 | ||
| Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics. | Q37650366 | ||
| Outcome of patients with incomplete resection after surgery for stage IB2/II cervical carcinoma with chemoradiation therapy | Q37726842 | ||
| Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy | Q37776652 | ||
| Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors. | Q51033082 | ||
| Hypoxia induces a hedgehog response mediated by HIF-1alpha. | Q51949665 | ||
| The prognostic significance of human epidermal growth factor receptor correlations in squamous cell cervical carcinoma. | Q52926362 | ||
| Expression profiling of G2/M phase regulatory proteins in normal, premalignant and malignant uterine cervix and their correlation with survival of patients. | Q53313238 | ||
| Expression of Ku80 in cervical cancer correlates with response to radiotherapy and survival. | Q54762009 | ||
| Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6 | Q60321491 | ||
| Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine | Q61626178 | ||
| Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity | Q61626183 | ||
| High Number of Intraepithelial CD8+Tumor-Infiltrating Lymphocytes Is Associated with the Absence of Lymph Node Metastases in Patients with Large Early-Stage Cervical Cancer | Q61626227 | ||
| Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner | Q62566479 | ||
| Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes | Q73526578 | ||
| Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer | Q77321076 | ||
| Expression and significance of PTEN and VEGF in canine mammary gland tumours | Q81228758 | ||
| PTEN and VEGF: possible predictors for sentinel lymph node micro-metastasis in breast cancer | Q81404347 | ||
| Relationship between suppression of E6 and E7 virus oncogenes and expression of apoptosis and cell cycle genes in cervical cancer culture | Q38339019 | ||
| Trends in cervical cancer incidence and mortality in the Baltic countries, Bulgaria and Romania | Q38444189 | ||
| Trends of cervical cancer mortality in the member states of the European Union | Q38449119 | ||
| Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. | Q38934630 | ||
| Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia | Q39296306 | ||
| PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts | Q39615005 | ||
| Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells | Q39619637 | ||
| Interruption of β-catenin suppresses the EGFR pathway by blocking multiple oncogenic targets in human glioma cells. | Q39641020 | ||
| A robust immunohistochemical assay for detecting PTEN expression in human tumors | Q39646962 | ||
| Inhibition of EGFR signaling augments oridonin-induced apoptosis in human laryngeal cancer cells via enhancing oxidative stress coincident with activation of both the intrinsic and extrinsic apoptotic pathways | Q39732329 | ||
| Nuclear EGFR contributes to acquired resistance to cetuximab | Q39812008 | ||
| PTEN regulates angiogenesis through PI3K/Akt/VEGF signaling pathway in human pancreatic cancer cells | Q39852386 | ||
| Differential expression of IGF-I and insulin receptor isoforms in HPV positive and negative human cervical cancer cell lines | Q39949508 | ||
| Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy | Q40040127 | ||
| Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: a COX-2 independent mechanism | Q40053483 | ||
| Expression of EGFR variant vIII promotes both radiation resistance and hypoxia tolerance | Q40130976 | ||
| Cyclooxygenase-2 transcription is regulated by human papillomavirus 16 E6 and E7 oncoproteins: evidence of a corepressor/coactivator exchange | Q40144444 | ||
| Late expression of nitroreductase in an oncolytic adenovirus sensitizes colon cancer cells to the prodrug CB1954. | Q40334522 | ||
| Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity | Q40396981 | ||
| Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway | Q40410769 | ||
| Molecular pathways executing the "trophic sentinel" response in HPV-16 E7-expressing normal human diploid fibroblasts upon growth factor deprivation | Q40589278 | ||
| Destabilization of the RB tumor suppressor protein and stabilization of p53 contribute to HPV type 16 E7-induced apoptosis | Q41071971 | ||
| Vitamin D3 analog, EB1089, inhibits growth of subcutaneous xenografts of the human colon cancer cell line, LoVo, in a nude mouse model | Q41122898 | ||
| Papillomavirus infections--a major cause of human cancers | Q41159507 | ||
| Robust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnostics | Q41885614 | ||
| The search for infectious causes of human cancers: where and why. | Q42459211 | ||
| Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans | Q42603429 | ||
| Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer | Q42981952 | ||
| HER2 codon 655 polymorphism is associated with advanced uterine cervical carcinoma | Q43212701 | ||
| Genomic integration of oncogenic HPV and gain of the human telomerase gene TERC at 3q26 are strongly associated events in the progression of uterine cervical dysplasia to invasive cancer. | Q43858287 | ||
| Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer | Q45037501 | ||
| Hepatocyte growth factor and c-Met in cervical intraepithelial neoplasia: overexpression of proteins associated with oncogenic human papillomavirus and human immunodeficiency virus | Q45729463 | ||
| A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer | Q45775812 | ||
| Inhibition of Wnt-1 signaling induces apoptosis in beta-catenin-deficient mesothelioma cells. | Q46129185 | ||
| Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy | Q46240097 | ||
| An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. | Q46248213 | ||
| Gene expression changes in cervical squamous cell carcinoma after initiation of chemoradiation and correlation with clinical outcome | Q46649036 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 403098 | |
| P577 | publication date | 2011-07-06 | |
| P1433 | published in | ISRN Oncology | Q26842194 |
| P1476 | title | Pathway profiling and rational trial design for studies in advanced stage cervical carcinoma: a review and a perspective | |
| P478 | volume | 2011 |
| Q37017045 | Characterization of the Tumor-Microenvironment in Patient-Derived Cervix Xenografts (OCICx) | cites work | P2860 |
Search more.